Understanding how a signaling molecule helps a fungus form protective structures
Official title: Investigating a signaling molecule that cooperates with quorum sensing to induce biofilm formation in C. neoformans
Funded at University of Georgia · NIH-10745957 · Data updated 2026-11-12
This study is looking at how a certain molecule helps a fungus called Cryptococcus neoformans form protective layers, which can make it harder to treat infections in people with weakened immune systems, like those with HIV/AIDS, and aims to find ways to better control this fungus.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project start | November 25, 2022 |
| Project end | October 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $188,750 |
| NIH project number | 5R21AI172787-02 |
| Project ID | NIH-10745957 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with compromised immune systems, particularly those living with HIV/AIDS, who are at risk for cryptococcal infections.
✕Less likely to help
Patients who do not have a compromised immune system or are not at risk for cryptococcal infections may not benefit from this research.
What this research studies
This research investigates how a specific signaling molecule interacts with quorum sensing to promote the formation of biofilms in the fungus Cryptococcus neoformans, which is known to cause serious infections in individuals with weakened immune systems, such as those with HIV/AIDS. The researchers aim to identify the genetic factors that regulate this biofilm formation, as well as the communication signals involved. By studying these processes, they hope to uncover new insights into how this pathogen behaves in the human body and how it can be better controlled. The approach includes genetic manipulation and observation of biofilm development under various conditions.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating infections caused by Cryptococcus neoformans.
How similar studies have gone: While the specific signaling mechanisms in Cryptococcus neoformans are less understood, similar approaches in studying biofilm formation in other fungi have shown promising results.
Where this research is happening
-
University of Georgia
Athens, United States Active
Researchers
- Principal investigator: Lin, Xiaorong — University of Georgia
- Study coordinator: Lin, Xiaorong
Related research
Other NIH-funded projects on the same topics.
-
BRD4 and NIPBL work together to control facial bone development
A study in mice and cell models will explore how BRD4 and NIPBL work together to control how genes are turned on in facial development, which could clarify causes of craniofacial disorders.
-
Sulfated glycosaminoglycan hydrogels to protect brain volume after traumatic injury
A new implantable gel made from specially sulfated sugars may help prevent brain shrinkage and improve function after a serious brain injury.
-
Understanding how Kaposi’s sarcoma virus switches on late genes during infection
Scientists are studying how the virus causing Kaposi’s sarcoma turns on late genes when its DNA copies itself, which could reveal new ways to treat cancer in people with AIDS.
-
Understanding how cells control signals and adhesion with the secretory pathway
A funded NIH project looks at how the cell’s secretory system shapes signals, receptors, and attachment to the outside of the cell, which can influence many human diseases.
-
AI-powered math and machine learning for bioscience and drug discovery
A broad NIH grant supports using advanced math and AI to better predict viral variants and aid drug discovery, with the goal of helping patients by accelerating pandemic response.
-
AI-driven platform to predict vaccine-escape variants and design mutation-proof antibodies
An AI-powered approach aims to anticipate SARS-CoV-2 variants that may dodge vaccines and to create antibodies that stay effective.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.